Angel News
Angel News

Back to Homepage

6th April 2017

6 April 

A novel antibiotic, which has been developed in Scotland for the treatment of Clostridium difficile, will take a step closer to being brought to market following the completion of a further round of funding led by prominent angel investment syndicate, Archangels, for MGB Biopharma.


Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:




Enter the characters in the image shown:

Back to Homepage